{
    "name": "magnesium supplement",
    "comment": "OTC",
    "other_names": [
        "Mag-Tab SR"
    ],
    "classes": [
        "Vitamins",
        "Water-Soluble"
    ],
    "source": "https://reference.medscape.com/drug/mag-tab-sr-magnesium-supplement-999755",
    "pregnancy": {
        "common": [
            "Not studied; magnesium crosses the placenta; effects of supplementation on neonate unknown",
            "Healthy growth and development of fetus depend on a steady supply of nutrients from the mother; however, taking large amounts of dietary supplements during pregnancy may be harmful to the mother and/or fetus and should be avoided"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Magnesium is present in breast milk; supplementation generally considered cmpatible with breastfeeding; however, taking large amounts of a dietary supplement while breast-feeding may be harmful to the mother and/or baby and should be avoided"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use with caution in patients with neuromuscular disease, including myasthenia gravis",
                "Diets high in fat may cause decreased magnesium absorption",
                "Monitor patients with severe renal impairment for magnesium toxicity; use caution",
                "When used for self-medication, not for long term use; not for use if nausea, vomiting, or abdominal pain present; patients with impaired kidney function should use under the supervision of healthcare professional",
                "When taking dietary supplements, it is especially important that patient inform healthcare professional as supplements may interfere with activity of prescription medications",
                "Magnesium supplements may worsen cardiac conditions",
                "Contact healthcare professional if after taking the supplement experience flushing, dizziness or fainting, muscle paralysis, trouble breathing",
                "Symptoms of overdose especially in patients with impaired kidney function may include drowsiness, slow heartbeat, trouble breathing, dizziness or fainting, blurred or double vision, coma",
                " "
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "baloxavir marboxil",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of baloxavir marboxil by  Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "raltegravir",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of raltegravir by  Other (see comment). Contraindicated. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alendronate",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of alendronate by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate  reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amikacin",
            "description": {
                "common": "magnesium supplement, amikacin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amlodipine",
            "description": {
                "common": "magnesium supplement, amlodipine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atracurium",
            "description": {
                "common": "magnesium supplement, atracurium.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bictegravir",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of bictegravir by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 6 hr after"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcitriol",
            "description": {
                "common": "magnesium supplement will increase the level or effect of calcitriol by  Other (see comment). Modify Therapy/Monitor Closely. Drug may increase absorption of magnesium in the intestine and colon, which increases risk of hypermagnesemia"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of ciprofloxacin by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 6hr after the quinolone"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisatracurium",
            "description": {
                "common": "magnesium supplement, cisatracurium.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clevidipine",
            "description": {
                "common": "magnesium supplement, clevidipine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferiprone",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of deferiprone by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 4 hr from polyvalent cation administration"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "delafloxacin",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of delafloxacin by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 6hr after the quinolone"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of demeclocycline by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "magnesium supplement, diltiazem.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolutegravir",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of dolutegravir by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 6 hr after"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxercalciferol",
            "description": {
                "common": "magnesium supplement will increase the level or effect of doxercalciferol by  Other (see comment). Modify Therapy/Monitor Closely. Drug may increase absorption of magnesium in the intestine and colon, which increases risk of hypermagnesemia"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxycycline",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of doxycycline by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eltrombopag",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of eltrombopag by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer under fasting conditions 2 hr before administering polyvalent cation or 4 hr after"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etidronate",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of etidronate by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate  reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "magnesium supplement, felodipine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of gabapentin by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 2 hr from polyvalent cation administration"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of gemifloxacin by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 3hr after the quinolone"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "magnesium supplement, gentamicin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibandronate",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of ibandronate by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate  reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "magnesium supplement, isradipine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of levofloxacin by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the quinolone or 2hr after the quinolone"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of levothyroxine by  Other (see comment). Modify Therapy/Monitor Closely. Drug may adsorb to magnesium; may decrease absorption by the intestinal tract; applies to oral forms; may separate administration of drugs by 4 hr"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "minocycline",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of minocycline by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of moxifloxacin by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 4hr before the quinolone or 8hr after the quinolone"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of mycophenolate by  Other (see comment). Modify Therapy/Monitor Closely. Drug may bind to magnesium ions in the GI tract, which decreases absorption; separate administration of drugs to minimize interaction"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "magnesium supplement, neomycin PO.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "magnesium supplement, nicardipine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "magnesium supplement, nifedipine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nimodipine",
            "description": {
                "common": "magnesium supplement, nimodipine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "magnesium supplement, nisoldipine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of omadacycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pancuronium",
            "description": {
                "common": "magnesium supplement, pancuronium.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penicillamine",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of penicillamine by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with polyvalent cations; may decrease absorption by the intestinal tract; applies to oral forms; may administer 1 hr from polyvalent cation administration"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "plazomicin",
            "description": {
                "common": "magnesium supplement, plazomicin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium phosphate",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of potassium phosphate by  Other (see comment). Modify Therapy/Monitor Closely. Drug may form a chelate with divalent cations; may decrease absorption by the intestinal tract; applies to oral forms; separate administration of drugs to avoid interaction"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risedronate",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of risedronate by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate  reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rocuronium",
            "description": {
                "common": "magnesium supplement, rocuronium.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of sarecycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptomycin",
            "description": {
                "common": "magnesium supplement, streptomycin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "magnesium supplement, succinylcholine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracycline",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of tetracycline by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiludronate",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of tiludronate by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Formation of a chelate  reduces absorption of the drug through intestinal tract; administer magnesium 2hr before or 2hr after the bisphosphonate derivative"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin",
            "description": {
                "common": "magnesium supplement, tobramycin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trientine",
            "description": {
                "common": "magnesium supplement will decrease the level or effect of trientine by  Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 1hr before the trietine or 1hr after the trientine"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vecuronium",
            "description": {
                "common": "magnesium supplement, vecuronium.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Each enhance the neuromuscular blocking effect of the other; may have negative respiratory effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "magnesium supplement, verapamil.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Calcium channel blockers may increase toxic effects of magnesium; magnesium may increase hypotensive effects of calcium channel blockers."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": null
        }
    ]
}